Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials

Solange Peters, Mary O’Brien, Dunson Ejedepang et al.|Lung Cancer|2021

Cited by 9